CSF2 and autoimmune pulmonary alveolar proteinosis: In a prospective trial conducted in Japan (25), 35 Japanese patients with autoimmune PAP inhaled GM-CSF over a total period of 24 weeks, using a regimen of initial high-dose followed by a maintenance low-dose.